The Food and Drug Administration accepted the application for review for daraxonrasib on July 22, putting the experimental pancreatic cancer pill on a formal review clock.
The drug is not approved. It has been reaching patients since May through an expanded access program run by Revolution Medicines and cleared by the FDA, and that program continues while the review proceeds. More than two thousand patients in the United States are now receiving daraxonrasib, the company's chief development officer told Medscape Medical News.
